[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-melanoma-skin-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-melanoma-skin-cancer":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,60,112,146,169,195,218],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":39,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100573965","electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-andor-secondary-visceral-localizations-of-any-histotype-100573965",false,"NCT06753136","Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype","Treatment of Visceral Localizations With Electrochemotherapy in Patients With Primary Visceral Tumors and\u002For Secondary Visceral Localizations, of Any Histotype: Monocenter, Single Arm, Clinical Investigation","Inclusion Criteria:\n\n* Male\u002FFemale ≥ 18 years\n* Ability to understand the proposed treatment and express an informed acceptance by signing the informed consent\n* Diagnosis of primary and\u002For secondary visceral localizations of any histotype\n* Patients who are not eligible for standard curative procedures\n\nExclusion Criteria:\n\n* Absolute contraindications to invasive procedures\n* Concomitant presence of brain, lung, bone metastases\n* Uncorrectable coagulation changes\n* Bleomycin allergy\n* Absolute contraindications to taking Bleomycin\n* Poor respiratory function or pulmonary fibrosis\n* Acute lung infections\n* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study","ALL","18 Years","99 Years",{"count":20,"type":21},24,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneous metastases of different tumor histotypes.\n\nAlthough still limited, the various experiences in the treatment of visceral localizations, particularly in liver metastases from colorectal cancer are promising and show that electrochemotherapy is a safe treatment, even in the case of lesions near large vessels or nerves. The investigators therefore propose a clinical investigation with a Medical Device according to EU Regulation 745\u002F2017, using electrochemotherapy (Cliniporator) with bleomycin for the treatment of visceral, primary or secondary, unresectable localizations, with percutaneous or intraoperative technique (laparoscopic or laparotomy), as needed.",[27,28,29,30,31,32,33,34,35,36,37,38],"Primary Visceral Tumors of Any Histotype","Visceral Lesions","Liver Cancer","Liver Metastasis Colon Cancer","Melanoma","Primary Pancreatic Tumor","Retroperitoneal Sarcoma","Abdominal and\u002For Peritoneal Localizations","Merkel Cell Carcinoma","Squamous Cell Carcinoma","Secondary Visceral Localizations of Any Histotype","Non-melanoma Skin Cancer",[40,41,42,43,44,45,46],"electrochemotherapy","visceral lesions","Laparoscopic procedure","Laparotomic procedure","Percutaneous procedure","bleomycin","medical device","RECRUITING","2026-04-09",{"date":50,"type":51},"2026-04-13","ACTUAL",{"date":53,"type":51},"2025-07-23",{"date":55,"type":21},"2030-02-28",{"name":57,"class":58},"Istituto Oncologico Veneto IRCCS","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":73,"conditions":74,"keywords":90,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":59},"100624518","phase-1-ebnk-001-allogeneic-nk-cells-with-low-dose-il-15--pembrolizumab-in-advanced-solid-tumors-100624518","NCT07410676","EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","An Open-Label Phase 1\u002F2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide\u002FFludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","EBNK-ST-001","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed advanced\u002Fmetastatic solid tumor that is relapsed\u002Frefractory after standard therapy (or no standard therapy available).\n* Measurable disease per RECIST v1.1 (or iRECIST if applicable).\n* ECOG performance status 0-1 (or 0-2 as allowed).\n* Adequate organ function (thresholds modeled on NK protocols):\n* Platelets ≥ 75,000\u002FµL; hemoglobin ≥ 9 g\u002FdL; ANC ≥ 1,000\u002FµL (unsupported by growth factors\u002Ftransfusions as defined).\n* eGFR ≥ 60 mL\u002Fmin\u002F1.73m².\n* AST\u002FALT ≤ 3× ULN.\n* Oxygen saturation ≥ 90% on room air (with PFT requirements if indicated).\n* LVEF ≥ 40% (by ECHO\u002FMUGA\u002FCMR).\n* If brain metastases are present, they must be stable for a defined period (example: ≥3 months) and not requiring escalating steroids.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Any condition requiring systemic immunosuppression (e.g., \\>5 mg prednisone\u002Fday or equivalent) during dosing window (topical\u002Finhaled may be allowed).\n* Active autoimmune disease requiring systemic immunosuppression.\n* Uncontrolled bacterial, fungal, or viral infection.\n* Receipt of investigational agent within 28 days before first study drug.\n* Live vaccine within 6 weeks prior to lymphodepletion.\n* Known HIV positivity or active hepatitis B\u002FC with detectable viral load (protocol may allow chronic asymptomatic hepatitis depending on risk plan).\n* Known allergy to investigational product components (example: albumin\u002Fhuman or DMSO).\n* Any medical\u002Fsocial condition likely to interfere with study compliance or increase risk.",{"count":69,"type":21},83,[71,72],"PHASE1","PHASE2","This Phase 1\u002F2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide\u002Ffludarabine (CY\u002FFLU) and supported with low-dose IL-15, administered either alone or in combination with pembrolizumab in adults with advanced\u002Fmetastatic solid tumors. The study will determine a recommended Phase 2 dose (RP2D) and explore signals of clinical activity using RECIST-based response criteria.",[75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"Cancer","Sarcoma","Leukaemia","Breast Cancer (Locally Advanced or Metastatic)","Lung Cancer (Diagnosis)","Colorectal Cancer","Melanoma (Skin Cancer)","Bladder Cancer","Kidney Cancer","Pancreatic Cancer Metastatic","Liver Cancer (Primary and Metastatic)","Ovarian Cancer","Esophageal Cancer","Glioblastoma","Non-Melanoma Skin Cancer",[91,92,93,94,95,96,97,98,99,89,31,82,100,101,102,87],"Natural killer cells","NK cell therapy","Solid tumors","IL-15","Breast Cancer","Lung and Bronchus Cancer","Prostate Cancer","Colorectal (Colon and Rectal) Cancer","CAR-T","Kidney (Renal Cell and Renal Pelvis) Cancer","Pancreatic Cancer","Stomach (Gastric) Cancer","2026-02-14",{"date":105,"type":51},"2026-02-18",{"date":107,"type":51},"2026-02-01",{"date":109,"type":21},"2029-12-21",{"name":111,"class":58},"Essen Biotech",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100545603","skin-cancer-and-hyperthermia-and-radiotherapy-100545603","NCT06384053","Skin Cancer and Hyperthermia and Radiotherapy","Skin Cancer and Hyperthermia and Radiotherapy - SAHARA a Two-arm, Open-label, Randomized Controlled Phase II Trial","SAHARA","Inclusion Criteria:\n\n* Personally signed and dated written informed consent\n* Histologically confirmed invasive non-melanoma skin cancer (NMSC), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) of any differentiation\n* ≥ T2 (TNM Classification 8th Edition)\n* Tumor thickness up to 2cm (Maximum Depth invasion and\u002For exophytic growth, measured on pathology report or imaging)\n* Local recurrence allowed, if primary treatment longer ago than 6 months (after primary treatment other than radiotherapy (RT))\n* Age ≥ 65 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2, with a life expectancy of more than 6 months\n* Presentation at the Swiss Hyperthermia Network (SHN) tumor conference mandatory\n\nExclusion Criteria:\n\n* Other histology than BCC or SCC\n* T1 tumor and\u002For N+ (according to TNM classification 8th edition)\n* Tumors after resection (R1 or R2 as well as adjuvant indication)\n* Tumor invasion into critical areas\n* Several lesions exceeding the capacity of one treatment\u002Fradiation field (multiple lesions within one treatment field are acceptable)\n* Previous (one month) or concurrent Chemo- or Immunotherapy\n* Patients with connective tissue disorders (e.g. Sclerodermia, Lupus erythematodes)\n* Lesions inside or in proximity (within 3cm) previously irradiated area\n* Medical immunosuppression\n* wIRA-specific exclusion criteria\n\n  * Tattoos in irradiated area\n  * Increased photosensitivity (either due to simultaneous treatment with photosensitivity-enhancing medications or conditions such as porphyria)","65 Years",{"count":122,"type":21},100,[24],"The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).",[126,127,38],"Basal Cell Carcinoma","Squamous Cell Carcinoma Skin",[129,130,131,132,133,134,135],"BCC","SCC skin","w-IRA hyperthermia","radiotherapy for non-melanoma skin cancer","non-melanoma Skin cancer","w-IRA combined with RT","hyperthermia","2025-06-11",{"date":138,"type":51},"2025-06-15",{"date":140,"type":51},"2025-01-01",{"date":142,"type":21},"2028-07-01",{"name":144,"class":58},"Kantonsspital Winterthur KSW",4,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":59},"100355308","effectiveness-of-fractionated-laser-resurfacing-to-protect-geriatric-skin-from-actinic-neoplasia-100355308","NCT03906253","Effectiveness of Fractionated Laser Resurfacing to Protect Geriatric Skin From Actinic Neoplasia","Inclusion Criteria:\n\n* Diagnosed with Actinic Keratosis within the past 6 months\n* At least 60 years of age, or older\n* Ability to comprehend procedures and risks versus benefits\n* Able to provide Informed Consent\n* Fair Skin (Fitzpatrick Type I or II)\n* Possess both Right and Left Forearms\n\nExclusion Criteria:\n\n* Uncontrolled Diabetes Mellitus\n* Not able to comprehend procedures or risks versus benefits\n* Pregnant or nursing\n* Large tattoos on forearms\n* History of abnormal healing or scarring (i.e., keloids)\n* Any disease that gets worse while in the sun\n* Use of topical or oral anti-inflammatory medication or steroids\n* Allergy to lidocaine\n* Current use of photosensitizing medication","60 Years",{"count":154,"type":21},72,[24],"This study is following up on previous studies that have demonstrated that geriatric subjects respond different to ultraviolet B (UVB) light than young subjects. The treatment of geriatric skin with dermal rejuvenation therapies (dermabrasion, fractionated laser resurfacing) restores the appropriate UVB response. Ongoing studies have tested the ability of fractionated laser resurfacing (FLR) to assess how long this wounding effect lasts-and have found that this appears to be a durable response which lasts for at least two years. The findings that FLR protects geriatric skin at two years is the impetus for this study.\n\nThis study is an interventional study to assess if FLR treatment of one forearm of geriatric subjects with multiple actinic keratosis will result in the short-term removal of actinic keratosis, and the long-term decrease in levels of future actinic keratosis and other non-melanoma skin cancers in comparison to the untreated arm.\n\nStudy length and visit: The first part of the study is completed in 1 day then there are follow up visits at 90 days and every 6 months for 5 years.",[158,159,89],"Actinic Keratoses","Aging","2025-03-24",{"date":162,"type":51},"2025-03-25",{"date":164,"type":51},"2018-01-10",{"date":166,"type":21},"2028-12",{"name":168,"class":58},"Wright State University",{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":5},"100512705","phase-3-nicotinamide-chemoprevention-for-keratinocyte-carcinoma-in-solid-organ-transplant-recipients---pivotal-trial-100512705","NCT05955924","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial","Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients: a Multicentre, Pragmatic Randomized Trial","SPRINTR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Kidney, liver, heart, or lung transplant at least two years ago\n* History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ\n* Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus)\n* Able to attend follow-up visits\n\nExclusion Criteria:\n\n* Use of nicotinamide or niacin (≥250 mg daily) within past 12 weeks\n* Untreated localized skin cancer at baseline (patient can enrol after skin cancer treatment)\n* Biopsy-confirmed acute rejection episode within the past 12 weeks\n* Active liver disease (high AST \\>3 times or bilirubin \\>1.5 times)\n* Severe kidney disease (estimated glomerular filtration rate \\\u003C20 mL\u002Fmin\u002F1.73 m2)\n* Solid organ or hematologic malignancy, invasive melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years\n* Pregnancy or lactation\n* Need for ongoing carbamazepine or primidone\n* Allergy to nicotinamide or any ingredient of the vitamin or placebo capsules",{"count":178,"type":21},396,[180],"PHASE3","As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical.\n\nNicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.",[38,183,184,185],"Carcinoma, Squamous Cell","Carcinoma, Basal Cell","Keratinocyte Carcinoma","2025-02-20",{"date":188,"type":51},"2025-02-21",{"date":190,"type":51},"2023-08-28",{"date":192,"type":21},"2027-08",{"name":194,"class":58},"Women's College Hospital",{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":202,"targetDuration":204,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":208,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":4},"100556339","dermoscopy-and-histopathology-in-non-melanocytic-skin-tumors-100556339","NCT06523816","Dermoscopy and Histopathology in Non-melanocytic Skin Tumors","Correlation Between Dermoscopy and Histopathology in Non-melanocytic Skin Tumors","Inclusion Criteria:\n\n* All patients with NMST clinically of both genders in all ages with positive dermoscopic findings and definite histopathologic diagnosis of NMST\n\nExclusion Criteria:\n\n* No exclusion criteria",{"count":203,"type":21},20,"10 Days","OBSERVATIONAL","The main aim of the study is to investigate the relation between dermoscopic findings in pre-operative diagnosis of non-melanocytic skin tumors and post-operative histopathology findings .",[38],"NOT_YET_RECRUITING","2024-07-23",{"date":211,"type":51},"2024-07-26",{"date":213,"type":21},"2024-10-01",{"date":215,"type":21},"2026-10-01",{"name":217,"class":58},"Assiut University",{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":152,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":22,"phases":226,"briefSummary":227,"conditions":228,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":59},"100549031","the-preventive-role-of-fractionated-laser-resurfacing-against-actinic-neoplasia-in-an-at-risk-geriatric-population-100549031","NCT06428721","The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population","Inclusion Criteria:\n\n* Adult Males and Females aged 60 and older\n* Have at least 5 AKs on each forearm\u002Fwrist, but no more than 10 to allow for easy monitoring\n* Skin type fair (Fitzpatrick I-II)\n* Females must be post-menopausal and not be on systemic hormone replacement therapy\n* Able to comprehend procedures and risks\n\nExclusion Criteria:\n\n* More than 10 AKs on an extremity\n* AKs that are large (2-3+, hyperkeratotic grade 3 lesions)\n* AKs that are very thick (\\>3 mm)\n* Medical history of diabetes\n* History of poor wound healing or scarring\n* Large tattoos that can interfere with study\n* Other serious health issues and other skin diseases that could interfere with the study\n* Recent (within 1 year) field therapies such as efudex cream or PDT to forearms\u002Fwrists.\n* Planning to leave region in next 5 years\n* Subjects with allergies to xylocaine will be excluded if they need this topical anesthetic.",{"count":225,"type":21},80,[24],"The purpose of this study is to determine if the Fractionated Laser Resurfacing (FLR) procedure can protect one forearm\u002Fwrist from precancerous actinic keratosis (AKs) as well as prevent skin cancer in older subjects with active AKs. This study builds on a similar study ongoing at the Dayton Veterans Administration dermatology clinic. This study is also testing if a photograph of the skin can be used to predict where the AKs and an skin cancers will form.",[158,159,89],{"date":230,"type":51},"2024-07-24",{"date":232,"type":51},"2024-03-20",{"date":234,"type":21},"2031-12",{"name":168,"class":58}]